# Miguel Martín

Source: https://onco.cc/people/miguel-martin/  
OnCo record `miguel-martin` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Miguel Martín is the founder of the Spanish breast cancer group GEICAM and a leader of adjuvant chemotherapy trials.

## Summary

Miguel Martín is Head of Medical Oncology at Hospital General Universitario Gregorio Marañón in Madrid and Chairman of GEICAM, the Spanish breast cancer research group he founded. His specialisms are breast cancer, adjuvant chemotherapy and cooperative group trials. He led trials of adjuvant docetaxel-based regimens, including BCIRG 001, the New England Journal of Medicine trial of adjuvant docetaxel for node-positive breast cancer. He has also been involved in CDK4/6 inhibitor trials including PALLAS and monarchE, which tested palbociclib and abemaciclib. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Head of Medical Oncology, Hospital General Universitario Gregorio Marañón; Chairman, GEICAM
- Specialisms: Breast cancer; Adjuvant chemotherapy; Cooperative group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Martin%20M%5BAuthor%5D%20GEICAM%20breast

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Palbociclib](https://onco.cc/drugs/palbociclib/)
- institutions: [Hospital General Universitario Gregorio Marañón](https://onco.cc/institutions/gregorio-maranon/)
- trials: [monarchE](https://onco.cc/trials/monarche/), [PALLAS & PENELOPE-B](https://onco.cc/trials/pallas-penelope-b/)
- people: [Ander Urruticoechea](https://onco.cc/people/ander-urruticoechea/)
- key papers: [monarchE: two years of abemaciclib after surgery in high-risk, hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-monarche-jco-2020/), [NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-natalee-nejm-2024/)
- companies: [GEICAM Spanish Breast Cancer Group](https://onco.cc/companies/geicam/)

---
JSON: https://onco.cc/api/v1/entities/miguel-martin.json